Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
rare diseases
Biotech
Rocket aborts mission to get rare disease gene therapy approved
Having already altered the journey of its rare disease gene therapy toward FDA approval, Rocket Pharmaceuticals has now aborted the mission entirely.
James Waldron
Oct 3, 2025 9:30am
FDA snubs Fortress' Zydus-partnered Menkes disease candidate
Oct 1, 2025 12:00pm
Applied Tx's stock drops on non-update for rare disease asset
Sep 29, 2025 10:57am
Ionis rare disease candidate ekes out phase 3 win
Sep 22, 2025 10:46am
Fierce Pharma
Stealth scores FDA approval for 1st Barth syndrome treatment
Sep 19, 2025 6:00pm
Regeneron's ultrarare disease phase 3 hits, teeing up filings
Sep 17, 2025 9:31am